Judging from the protease selectivity data and potency of MM3122 and other new compounds, these are predicted to also show corresponding anticancer activity, in particular for HGF-driven prostate cancer for which TMPRSS2 is known to play a key role (30, 51). Here, TMPRSS2 is linked to prostate cancer.